These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...
In a retrospective cohort of patients with central nervous system manifestations of multiple myeloma, ide-cel CAR T-cell ...
In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear ...
Pirtobrutinib, a third-generation BTK inhibitor, showed superior progression-free survival and lower treatment ...
Initial therapy with sonrotoclax and zanubrutinib showed strong efficacy and acceptable safety in untreated CLL/SLL.
Ira Zackon, MD, discusses the real-world uptake of bispecific antibodies in community oncology practices and what it reveals about their utilization in relapsed/refractory multiple myeloma treatment.